随着精准肿瘤学在胆道肿瘤（BTC）中的重要性日益提升，本次回顾性单中心分析的目的是描述在CCC慕尼黑洛伊迪格大学分子肿瘤委员会（MTB）中经过全面基因组分析（CGP）讨论的BTC患者的临床和分子特征。在这个单中心观察性研究中，我们纳入了2017年5月29日至2022年7月25日期间曾在机构MTB讨论过的肝内胆管细胞癌（iCCA）、肝外胆管细胞癌（eCCA）和胆囊癌（GB）的BTC患者。患者的随访持续到2023年1月31日。通过查阅病例回顾性收集数据，并进行MTB建议意见。总共登记了153例MTB患者，中位随访时间为15个月。测试成功率为81.7%。CGP检测到我们的BTC患者中35.3%的可靶向改变（最常见的是ARID1A/ERBB2/IDH1/PIK3CA/BRAF突变和FGFR2融合）。分子引导治疗的建议占46.4%。其中，19.4%的患者接受了推荐的靶向治疗。接受推荐治疗的患者，治疗反应率为57%，中位总生存时间为19个月（未治疗组为8个月）。1.45的无进展生存比例表明分子引导治疗具有临床益处。与先前工作一致，我们的系列研究证实了在BTC患者中进行全面基因组分析的可行性和临床实用性。随着BTC中具有临床活性的靶向药物的增加，CGP应成为管理这类患者的标准医疗。© 2023年。作者。

With the rising importance of precision oncology in biliary tract cancer (BTC), the aim of this retrospective single-center analysis was to describe the clinical and molecular characteristics of patients with BTC who underwent comprehensive genomic profiling (CGP) and were discussed in the CCCMunichLMU molecular tumor board (MTB).In this single-center observational study, we included BTC patients with intrahepatic cholangiocarcinoma (iCCA), extrahepatic CCA (eCCA), and gallbladder cancer (GB), who had been discussed in the institutional MTB from May 29, 2017, to July 25, 2022. Patients were followed up until 31 January 2023. Data were retrospectively collected by review of medical charts, and MTB recommendation.In total, 153 cases were registered to the MTB with a median follow-up of 15 months. Testing was successful in 81.7% of the patients. CGP detected targetable alterations in 35.3% of our BTC patients (most commonly ARID1A/ERBB2/IDH1/PIK3CA/BRAF-mutations and FGFR2-fusions). Recommendations for molecularly guided therapy were given in 46.4%. Of those, treatment implementation of targeted therapy followed in 19.4%. In patients receiving the recommended treatment, response rate was 57% and median overall survival was 19 months (vs 8 months in the untreated cohort). The progression-free survival ratio of 1.45 suggest a clinical benefit of molecularly guided treatment.In line with previous work, our series demonstrates feasibility and clinical utility of comprehensive genomic profiling in BTC patients. With the growing number of targeted agents with clinical activity in BTC, CGP should become standard of care in the management of this group of patients.© 2023. The Author(s).